Category: Pharma Industry

GSK Announces Refunds for 340B Overcharges

August 20, 2024 Shannon Young, Associate Editor/Senior Writer Views

GlaxoSmithKline will refund covered entities that purchased certain formulations of a severe asthma treatment in 2022.

GlaxoSmithKline (GSK) will refund covered entities that purchased certain formulations of a severe asthma treatment medication in the third quarter [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B ESP Updates Claims Submission Policy, Stakeholders Voice Concerns About Compliance

August 15, 2024 Shannon Young, Associate Editor/Senior Writer Views

Second Sight Solutions updated 340B ESP's terms of use on Oct. 4.

340B covered entities could soon be required to share new information—including reimbursement amounts, ship to dates and ship to locations—as [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

State Contract Pharmacy Lawsuit Weekly Roundup: AstraZeneca Defends Subpoenas; Updates in Missouri, Mississippi, Maryland

August 15, 2024 Shannon Young, Associate Editor/Senior Writer & William Newton, Associate Editor/Senior Writer Views

Lawsuits challenging 340B contract pharmacy access laws recently heated up in Missouri, Mississippi and Maryland.

Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Former Pfizer Exec. Slams 340B, Says IRA Will Worsen Program in New Op-Ed

August 15, 2024 Shannon Young, Associate Editor/Senior Writer Views

Kirsten Axelsen, a consultant and former Pfizer executive, cautioned that the 340B program “will be even worse” under the IRA in an Aug. 13 op-ed.

A former Pfizer executive and current biopharmaceutical consultant took aim this week at what she called the “poorly managed” 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

After Failing To Disclose Conflict of Interest, JAMA Issues Correction to Piece Calling for Increased 340B Oversight and Transparency

August 13, 2024 Bella Czajkowski, National Correspondent Views

JAMA corrected an opinion piece on the 340B program to disclose one author's drug industry ties, shortly after 340B Report reported on the omission.

Two weeks after publishing an opinion piece that called for increased 340B program oversight and provider transparency, JAMA issued a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

UPDATED: AbbVie Ends Voluntary 340B Discount Pricing for Dozens of Orphan Drugs

August 13, 2024 Shannon Young, Associate Editor/Senior Writer Views

AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to covered entities subject to such exclusions.

AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to rural referral centers (RRC), sole [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

HRSA Seeks Public Comment On ADR Process and Required Administrative Load

August 13, 2024 Bella Czajkowski, National Correspondent Views

HRSA is seeking stakeholder comments on the administrative burden of the updated 340B ADR process.

The Health Resources and Services Administration (HRSA) has requested public comment on how petitioners file their initial claims in the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Two New Drug Industry Lawsuits Challenge 340B Contract Pharmacy Access Laws in Kansas, Missouri

August 13, 2024 William Newton, Associate Editor/Senior Writer Views

Drugmaker Novartis and trade organization PhRMA each recently filed a new lawsuit against separate state 340B contract pharmacy access laws.

A powerful brand name drug industry trade group has filed suit against a Kansas law prohibiting drugmaker 340B contract pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

J&J Exempts Maryland, Mississippi from Contract Pharmacy Restrictions

August 13, 2024 William Newton, Associate Editor/Senior Writer Views

Drugmaker J&J announced for the first time that it is exempting certain states from its 340B contract pharmacy restrictions.

Pharmaceutical giant Johnson & Johnson (J&J) is exempting covered entities in Maryland and Mississippi from its contract pharmacy restrictions, marking [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

State Contract Pharmacy Lawsuit Weekly Roundup: AstraZeneca Subpoenas in Arkansas, Mississippi; Minnesota AG’s Defense

August 8, 2024 William Newton, Associate Editor/Senior Writer & Shannon Young, Associate Editor/Senior Writer Views

Lawsuits challenging 340B contract pharmacy access laws recently heated up in Missouri, Mississippi and Maryland.

Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live